PARK CITY, Utah — APX3330, an investigational systemic treatment for diabetic retinopathy, showed encouraging outcomes in the phase 2 ZETA-1 trial, paving the way to phase 3.
“It is a promising oral candidate for slowing the progression of diabetic retinopathy ... a noninvasive approach to our diabetic patients,” Veeral Sheth, MD, MBA, FACS, FASRS, said at Clinical Trials at the Summit.
APX3330 (Ocuphire Pharma) is a selective inhibitor of Ref-1, which is responsible for three distinct pathways: angiogenesis, oxidative stress and inflammation, he said. By simultaneously